The Department of Justice (DoJ) claims that Biohaven – before being acquired by Pfizer – paid "improper remuneration" to some Nurtec ODT (rimegepant) prescribers in the form of speaker fees ...
Sales of Nurtec ODT (rimegepant) – approved as an oral therapy for migraine prevention and acute treatment – reached $194 million in sales in the fourth quarter of 2022. It competes with other ...